Back
Virtus AllianzGI Equity & Convertible Income Fund Vs. Halozyme Therapeutics Industry Stock Comparison
Buy
60
NIE
Virtus AllianzGI Equity & Convertible Income Fund
Last Price:
23.87
Seasonality Move:
2.87%
Sell
39
HALO
Halozyme Therapeutics
Last Price:
42.56
Seasonality Move:
17.03%
Buy
60
Virtus AllianzGI Equity & Convertible Income Fund (NIE)
is a Buy
Is Virtus AllianzGI Equity & Convertible Income Fund a Buy, Sell or Hold?
- The current Virtus AllianzGI Equity & Convertible Income Fund [NIE] share price is $23.54. The Score for NIE is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.
- NIE is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
39
Halozyme Therapeutics (HALO)
is a Sell
Is Halozyme Therapeutics a Buy, Sell or Hold?
- The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
- HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
NIE Stock Price Chart
What is Virtus AllianzGI Equity & Convertible Income Fund's stock price today?
-
The Virtus AllianzGI Equity & Convertible Income Fund share price today is $23.54
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and NIE is experiencing selling pressure, which indicates risk of future bearish movement.
HALO Stock Price Chart
What is Halozyme Therapeutics's stock price today?
-
The Halozyme Therapeutics share price today is $45.65
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.
NIE Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.2 | Buy |
| Relative Strength Index (14 RSI): | 53.04 | Buy |
| Chaikin Money Flow: | -45454 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (23.12 - 23.78) | Buy |
| Bollinger Bands (100): | (22.32 - 23.48) | Buy |
HALO Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.02 | Sell |
| Relative Strength Index (14 RSI): | 30.2 | Sell |
| Chaikin Money Flow: | -7140517 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (49.94 - 58.56) | Sell |
| Bollinger Bands (100): | (52.16 - 60.38) | Sell |
NIE Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 23.82 | Sell |
| 20-day SMA: | 23.45 | Buy |
| 50-day SMA: | 23.15 | Buy |
| 200-day SMA: | 22.55 | Buy |
| 8-day EMA: | 23.72 | Sell |
| 20-day EMA: | 23.52 | Buy |
| 50-day EMA: | 23.22 | Buy |
| 200-day EMA: | 22.51 | Buy |
HALO Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 57.53 | Sell |
| 20-day SMA: | 54.48 | Sell |
| 50-day SMA: | 56.18 | Sell |
| 200-day SMA: | 48.93 | Sell |
| 8-day EMA: | 55 | Sell |
| 20-day EMA: | 55.41 | Sell |
| 50-day EMA: | 55.64 | Sell |
| 200-day EMA: | 50.73 | Sell |
Virtus AllianzGI Equity & Convertible Income Fund Earnings Growth & NIE Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Halozyme Therapeutics Earnings Growth & HALO Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.35 per share, and an increase next year of $0.56 per share.
Virtus AllianzGI Equity & Convertible Income Fund Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Halozyme Therapeutics Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||